MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma

MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma

Background Phosphorylated peptides presented by MHC molecules represent a new class of neoantigens expressed on cancer cells and recognized by CD8 T-cells. These peptides are promising targets for cancer immunotherapy. Previous work identified an HLA-A*0201-restricted phosphopeptide from insulin rec...

Full description

Saved in:
Bibliographic Details
Main Authors: Mark E Smolkin, Gina R Petroni, Kimberly A Chianese-bullock, Kelly T Smith, Geoffrey Weiss, Nico Buettner, Mark Cobbold, Jeffrey Shabanowitz, Nikole Varhegyi, Elizabeth Gaughan, Victor H Engelhard, Rebecca C Obeng, Kara L Cummings, Angela L Ambakhutwala, Amanda Lulu, Paisley Myers, Keira E Mahoney, Emily H Hall, Kathleen Haden, Donald F Hunt, Craig L Slingluff, Jr
Format: Article
Language:English
Published: BMJ Publishing Group 2020-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/1/e000262.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/8/1/e000262.full

Similar Items